Track topics on Twitter Track topics that are important to you
Experimental studies have showed that statins reduce left ventricular hypertrophy. The main objective is to observe the reduction of left ventricular hypertrophy with statins in hypertensive patients. The hypothesis is that patients treated with statins will have a reduction of at least 10% compared with patients treated only with antihypertensive treatment.
Experimental studies have showed that statins reduce left ventricular hypertrophy. The main objective is to observe the reduction of left ventricular hypertrophy with statins in hypertensive patients. The hypothesis is that patients treated with statins will have a reduction of at least 10% compared with patients treated only with antihypertensive treatment. The study will be conducted at Cardiovascular Unit Hospital 1o de october in Mexico City. Patients must have hypertension grade 2 according to the European Hypertension Guides, and must have LDL-C >130mg/dl. Patient will be assigned randomly to four arms of treatment, and will be follow up for one year. Left ventricular mass will be measured every 6 months, and LDL-C will be measured every 2 months.
Allocation: Randomized, Control: Uncontrolled, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Left Ventricular Hypertrophy
Valsartan plus pravastatin, Valsartan plus simvastatin, Valsartan plus simvastatin plus ezetimib, Only valsartan
Cardiovascular Unit Hospital 1o de October
Hospital Universitario 12 de Octubre
Published on BioPortfolio: 2014-08-27T03:32:44-0400
This study will assess and compare the efficacy and safety of valsartan and the combination of valsartan and simvastatin in patients with high blood pressure and high cholesterol.
The purpose of the present study is to assess the non-inferiority of the efficacy and safety of fixed dose combination of 5 mg amlodipine and 80 mg valsartan compared to 160 mg valsartan i...
The purpose of this was to evaluate valsartan 320mg compared to valsartan 160 mg in terms of blood pressure reduction in a patient population of mild to moderate hypertensives
The purpose of this study is to compare improvement percentage of urinary albumin excretion between valsartan 80 mg- and valsartan 160 mg-based therapy in patient with morning hypertension...
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan + hydrochlorothiazide (HCTZ) 160/12.5 mg comp...
The Prospective comparison of angiotensin receptor antagonist Valsartan and neprilysin inhibitor Sacubitril with angiotensin-converting enzyme inhibitor (enalapril) to determine impact on Global Morta...
In this study, the protective effect of valsartan against glycerol-induced acute kidney injury (AKI) in male albino rats was investigated. Valsartan is used to treat high blood pressure and congestive...
A reduction in the rate of death and hospitalisations in patients with heart failure (HF) with reduced ejection fraction receiving sacubitril/valsartan compared to enalapril was demonstrated in the PA...
A 58-year-old man with previous mitral/aortic mechanical-valve replacement, aortic root repair, and coronary disease developed severe left-ventricular dysfunction following AV-node ablation/single-cha...
The objective of this study was to investigate the transfer behavior of the weakly acidic BCS class II drug valsartan from the stomach to the small intestine during fasted and fed states. An in vitro ...
A pharmaceutical preparation of amlodipine and valsartan that is used for the treatment of HYPERTENSION.
A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.
A pharmaceutical preparation of ezetimibe and simvastatin that is used in the treatment of HYPERCHOLESTEROLEMIA and HYPERLIPIDEMIAS.
An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).
A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.
Cardiology is a specialty of internal medicine. Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...
The United States Food and Drug Administration (FDA) has approved on October 8th 2013 Adempas® (riociguat) tablets for: (i) the treatment of adults with persistent/recurrent chronic thromboembolic pulmonary hypertension (CTEPH) (WHO* Group 4) after ...